Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 269

1.

From anti-Parkinson's drug rasagiline to novel multitarget iron chelators with acetylcholinesterase and monoamine oxidase inhibitory and neuroprotective properties for Alzheimer's disease.

Zheng H, Amit T, Bar-Am O, Fridkin M, Youdim MB, Mandel SA.

J Alzheimers Dis. 2012;30(1):1-16. doi: 10.3233/JAD-2012-120013. Review.

PMID:
22387411
3.

Site-activated chelators derived from anti-Parkinson drug rasagiline as a potential safer and more effective approach to the treatment of Alzheimer's disease.

Zheng H, Fridkin M, Youdim MB.

Neurochem Res. 2010 Dec;35(12):2117-23. doi: 10.1007/s11064-010-0293-1. Epub 2010 Oct 28.

PMID:
20981484
5.

Implications of co-morbidity for etiology and treatment of neurodegenerative diseases with multifunctional neuroprotective-neurorescue drugs; ladostigil.

Youdim MB, Amit T, Bar-Am O, Weinreb O, Yogev-Falach M.

Neurotox Res. 2006 Dec;10(3-4):181-92. Review.

PMID:
17197368
6.

Selective acetylcholinesterase inhibitor activated by acetylcholinesterase releases an active chelator with neurorescuing and anti-amyloid activities.

Zheng H, Youdim MB, Fridkin M.

ACS Chem Neurosci. 2010 Nov 17;1(11):737-46. doi: 10.1021/cn100069c. Epub 2010 Oct 4.

7.
8.

Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer's disease drugs.

Weinreb O, Mandel S, Bar-Am O, Yogev-Falach M, Avramovich-Tirosh Y, Amit T, Youdim MB.

Neurotherapeutics. 2009 Jan;6(1):163-74. doi: 10.1016/j.nurt.2008.10.030. Review.

10.

Novel chelators targeting cell cycle arrest, acetylcholinesterase, and monoamine oxidase for Alzheimer's therapy.

Zheng H, Fridkin M, Youdim MB.

Curr Drug Targets. 2012 Jul;13(8):1089-106. Review.

PMID:
22676912
11.

Site-activated chelators targeting acetylcholinesterase and monoamine oxidase for Alzheimer's therapy.

Zheng H, Youdim MB, Fridkin M.

ACS Chem Biol. 2010 Jun 18;5(6):603-10. doi: 10.1021/cb900264w.

PMID:
20455574
12.
13.

Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.

Guay DR.

Am J Geriatr Pharmacother. 2006 Dec;4(4):330-46. Review.

PMID:
17296539
14.

Site-activated multifunctional chelator with acetylcholinesterase and neuroprotective-neurorestorative moieties for Alzheimer's therapy.

Zheng H, Youdim MB, Fridkin M.

J Med Chem. 2009 Jul 23;52(14):4095-8. doi: 10.1021/jm900504c.

PMID:
19485411
17.

Therapeutic targets and potential of the novel brain- permeable multifunctional iron chelator-monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer's disease.

Avramovich-Tirosh Y, Amit T, Bar-Am O, Zheng H, Fridkin M, Youdim MB.

J Neurochem. 2007 Jan;100(2):490-502. Epub 2006 Nov 27.

18.
19.

A novel anti-Alzheimer's disease drug, ladostigil neuroprotective, multimodal brain-selective monoamine oxidase and cholinesterase inhibitor.

Weinreb O, Amit T, Bar-Am O, Youdim MB.

Int Rev Neurobiol. 2011;100:191-215. doi: 10.1016/B978-0-12-386467-3.00010-8. Review.

PMID:
21971009
20.

Supplemental Content

Support Center